The aldosterone-renin ratio (ARR) is considered to be the most reliable and sensitive screening parameter for primary aldosteronism (PA). However, little is known regarding how stroke influences the ARR. We herein present a case of a 35-year-old man who was ultimately found to have PA after diagnostic challenges. The patient showed an atypical ARR in the acute phase of cerebral hemorrhage. We therefore conclude that the ARR may be inappropriately decreased immediately after stroke in patients with PA, presumably due to sympathetic activation and the effects of medications. When diagnosing PA in patients with stroke, we suggest reevaluating the ARR in the stable phase.
Introduction
Primary aldosteronism (PA) is one of the most common causes of secondary hypertension, accounting for 5-13% of all cases of hypertension (1, 2) , although it is generally underdiagnosed. PA is defined as the autonomous secretion of aldosterone resulting in the excessive retention of sodium and water, which subsequently leads to resistant hypertension. PA is usually caused by the presence of an adrenal adenoma or unilateral or bilateral adrenal hyperplasia. In rare cases, the disease may be due to an inherited condition (3), such as glucocorticoid-remediable aldosteronism. PA is associated with higher rates of cardiovascular and cerebrovascular morbidity and mortality compared to those observed in age-and sex-matched patients with essential hypertension (4-7). For example, the incidence of cerebrovascular accidents is 12.9% among patients with PA in comparison with 3.4% among patients with essential hypertension (6) . Surgical and medical interventions, such as the administration of mineralocorticoid receptor (MR) antagonists, can significantly improve long-term outcomes (7) . Therefore, it is crucial to diagnose PA in a timely manner.
The aldosterone-renin ratio (ARR) is the most reliable and accessible screening parameter for PA (1, 2, 8) . The ARR is calculated based on the plasma aldosterone concentration (PAC, ng/dL) and plasma renin activity (PRA, ng/ mL/hr) and has a high sensitivity for PA. However, several different cut-off values for the ARR have been proposed (8, 9) . In general, an ARR of >20 ng/dL per ng/mL/hr is suggestive of PA, and the possibility of PA increases with a concomitant PAC of >15 ng/dL (1) . However, imaging studies, including abdominal computed tomography (CT), are less sensitive in such cases, as aldosterone-producing adenomas measuring less than 5 mm in diameter are often difficult to detect on CT and adrenal hyperplasia is indistinguishable from normal adrenal glands on CT scans. Therefore, the ARR is currently considered to be the screening test of choice for PA. Nevertheless, as with all biochemical screening tests, the ARR has limitations. Certain medications and other pathophysiological conditions, such as differences in the patient's posture during blood sampling (i.e. sit- 
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ting or supine), hypo-or hyperkalemia, dietary sodium intake and renal impairment, are known to modify the ARR (1, 2, 9) . Therefore, it is recommended that the ARR be reevaluated after correcting these potentially influential factors.
We herein present a case of PA with diagnostic challenges in which the patient presented with an atypical reninaldosterone profile in the acute phase of cerebral hemorrhage. We discuss the potential pitfalls of which clinicians should be aware when diagnosing PA.
Case Report
A 35-year-old overweight man [height: 157 cm, body weight: 71 kg, body mass index (BMI): 28.1 kg/m 2 ] with a history of early-onset hypertension starting at 29 years of age who was currently under treatment with valsartan and nifedipine (dosage unknown) presented to the emergency department with a hypertensive emergency associated with dysarthria and right-sided hemiparesis. His blood pressure was 240/140 mmHg at presentation following medication non-compliance for two weeks. According to his medical record, his regular baseline blood pressure was controlled at approximately 140/80 mmHg with medication. A head CT scan revealed acute intracranial hemorrhage in the pontine and right cerebellum (Fig. 1A) . Intravenous glycerol was administered to prevent cerebral edema, with the continuous infusion of nicardipine (5 μg/min/kg) to control the patient's blood pressure. The nicardipine infusion was subsequently switched to oral azelnidipine and doxazosin on the second day, and the azelnidipine was switched to oral nifedipine on the third day (Fig. 2) . The patient was maintained on an nil per os (NPO) status with intravascular hydration (2,400 mL/ day) for three to four days after admission, then started on a sodium-restricted diet with hydration by mouth ad libitum. His neurological symptoms gradually improved from an National Institute of Health (NIH) stroke scale (NIHSS) score of 4 to 0 on day 14, without any residual symptoms.
Due to the detection of early-onset hypertension, hypokalemia (2.7 mEq/L) and slight metabolic alkalosis (pH 7.46, HCO3 26 mmol/L, base excess 2.2 mmol/L) on the first day of admission, we considered a diagnosis of secondary hypertension due to PA. An unenhanced CT scan showed a 10-mm right adrenal mass (Fig. 1B, arrow) with low attenuation (2 Hounsfield Units), indicating a lipid-rich structure consistent with a cortical adenoma (10) . In contrast to our expectations, endocrinology tests performed on hospital day 2 (Table 1) showed a PRA of 15.0 ng/mL/hr, PAC of 11.3 ng/dL and ARR of 0.75, which are not consistent with a diagnosis of PA. However, follow-up ARR tests showed a gradual increase in this parameter, which is consistent with PA. On day 12, the PRA decreased to 1.9 ng/mL/hr, the PAC increased to 19.3 ng/dL and the ARR increased to 10.2. On day 20, the PRA was 0.8 ng/mL/hr, the PAC was 23.2 ng/dL and the ARR was 29.0 (Table 1) . In addition to renin-aldosterone profiles, we determined the levels of catecholamines and their metabolites in the plasma and urine. Consequently, the morning plasma noradrenaline and dopamine (day 2) and urinary noradrenaline, dopamine and normetanephrine (day 7) levels were each elevated within two-fold of the upper limit of normal. The levels of urinary metabolites of catecholamines were measured on follow-up examinations, which showed that the urinary normetanephrine value normalized on day 19 (Table 1) .
Because the ARR exceeded 20 on day 20, a captoprilchallenge test and rapid adrenocorticotropic hormone (ACTH)-stimulation test were performed as confirmatory tests for PA on days 30 and 31, respectively. For the captopril-challenge test, 50 mg of captopril was administered orally and blood samples were obtained prior to (baseline) and at 60 and 90 minutes after administration. The PRA was 1.3 ng/mL/hr at baseline, which was somewhat higher than that observed on day 20. Meanwhile, the ARR was 16.9 (less than 20, as discussed later). After the captopril challenge, the PRA slightly increased to 1.5 ng/mL/hr, while the PAC decreased from 22.0 ng/dL (baseline) to 13.4 ng/dL (90 minutes, 40% decrease). These data are not consistent with the typical findings of PA (PAC >15.0 ng/dL and ARR >20 ng/dL per ng/mL/hr) ( Table 2) .
A rapid ACTH-stimulation test with 0.25 mg of Cortro- syn (cosyntropin, Daiichi-Sankyo, Tokyo, Japan) elicited a marked increase in the PAC value to 29.4 ng/dL at 90 minutes, whereas the cortisol level was 27.4 μg/dL; thus, the maximum PAC/cortisol ratio after ACTH-stimulation was 1.07 ( Table 2 ). The results of the rapid ACTH-stimulation test met the criteria for PA proposed by Omura et al. (11) , in that the maximum PAC/cortisol ratio was greater than 0.85 in the setting of a PAC of >12 ng/dL and PRA of <1.0 ng/mL/hr. Despite the negative captopril test, the spontaneous plasma ARR value of >20 ng/dL per ng/mL/h, 10-mm lowattenuation mass on abdominal CT and ACTH-stimulation test with a PAC/cortisol ratio above 0.85 suggested a diagnosis of PA. Therefore, we proceeded with an adrenal venous-sampling study (Table 2) .
Prior to ACTH injection, the PAC values on the right and left sides were 3,480.0 ng/dL and 66.1 ng/dL, respectively. The cortisol-corrected aldosterone ratio from the high side to the low side was more than 2:1, which met the criteria for PA proposed by Rossi et al. (12) . The PAC values on the right and left sides 30 minutes after the bolus ACTH injection were 3,160.0 ng/dL and 256.0 ng/dL, respectively. These results met the criteria for PA (PAC >1,400 ng/mL) proposed by Omura et al. (11) (Table 2 ). Based on these findings, we diagnosed the patient with unilateral PA caused by a right cortical adenoma.
Laparoscopic right adrenalectomy was performed three months after the patient's cerebral hemorrhage. The pathology results confirmed the presence of a clear-cell adrenal adenoma (Fig. 1C-E) . The patient's postoperative course was uneventful, and his PRA and PAC levels returned to normal (PRA: 2.0 ng/mL/hr, PAC: 6.8 ng/dL) on postoperative day 7. In addition, his blood pressure control was significantly improved at the one-year follow-up visit, being within the range of 120 mmHg systolic, under treatment with nifedipine (60 mg daily) and valsartan (80 mg daily).
Discussion
In this report, we discuss the diagnostic challenges of PA in the acute phase of cerebral hemorrhage, focusing specifically on the atypical renin-aldosterone profile observed at presentation and the interpretation of confirmatory tests for PA.
In the present case, the endocrinology data, including an elevated PRA, PAC within the normal range and low ARR obtained on hospital day 2, were atypical for PA. Although the ARR is currently the most reliable screening tool for PA, it is easily influenced by several factors, such as day-to-day variations, dietary sodium intake, the sampling time, posture, age and medications (1, 2, 9, 13, 14) . In this case, we speculate that sympathetic nerve activation and the effects of medications may be two major factors causing the initial "false-negative" low ARR value.
Hiraiwa et al. (15) reported a similar case of PA in which the patient presented with an atypical ARR in the acute phase of cerebral hemorrhage. In that case, the plasma norepinephrine and urinary metanephrine levels were elevated to approximately five times above the upper limit of normal at presentation and normalized on day 23. In the acute phase of intracranial hemorrhage, sympathetic nerve activation occurs secondary to an elevated intracranial pressure (16) , which stimulates renin secretion (17) . Leow et al. (18) reported an excessive amount of catecholamines and metanephrine triggered by sympathetic dysautonomia in the setting of acute intracranial hemorrhage, describing this phenomena as "biochemically pseudopheochromocytoma," as the plasma catecholamine and urinary metabolite levels mimic the endocrinological laboratory findings of pheochromocytoma. Patients with a large hematoma volume develop significantly elevated urinary catecholamine metabolite levels (16) . In most cases of acute cerebral hemorrhage without pheochromocytoma, however, the increase in plasma catecholamines and urinary metabolites is slight to moderate and the levels remain within three-to five-fold of the upper limit of normal (15) (16) (17) . Therefore, it is not generally difficult to make the differential diagnosis of pheochromocytoma. Nevertheless, one should exclude concomitant pheochromocytoma by repeating the tests of the catecholamine levels during the stable phase, as pheochromocytoma is associated with a higher incidence of cerebral bleeding (2%) and cerebral infarction (3%) (19) . The timeframe for normalization of catecholamines has been previously discussed. In general, the urinary catecholamine metabolite levels peak between days 3 and 10 after the onset of bleeding (16). The surge in catecholamines then normalized after one month, corresponding with the duration of diaschisis and maximum neurological deficits (15, 18) . In the present case, the morning plasma catecholamine and urinary normetanephrine levels were elevated on days 2 and day 7, respectively, and remained within two-fold of the upper limit of normal, although the urinary normetanephrine value normalized on day 12. These findings are significant and may have affected the ARR, although they were relatively mild compared with those of previous reports (15, 16, 18) .
Along with sympathetic activation, the administration of osmotic diuretics and antihypertensive drugs may have contributed to the atypical ARR at presentation observed in this case. Diuretics stimulate renin production via volume contraction, thereby lowering the ARR (9, 20) . The concentrated glycerol administered under emergency conditions may have led to a "falsely" low ARR. In addition, the continuous infusion of nicardipine and oral nifedipine may have affected the ARR. Dihydropyridine calcium-channel blockers (CCBs) are known to suppress calcium-dependent aldosterone secretion in vivo and in vitro (21) . However, the effects of dihydropyridine CCBs on the ARR in screening for PA are generally mild and controversial compared with those of other antihypertensive agents, such as diuretics, angiotensinconverting enzyme-inhibitors and angiotensin-receptor blockers. For example, Mulatero et al. (22) studied the effects of various antihypertensive agents, including amlodipine, on hypertensive patients positive for ARR screening tests (ARR>50 and PAC>15) after a washout period of previous antihypertensive therapy and found that only one of the 55 patients taking amlodipine (1.8%), compared to four of the 17 patients taking irbesartan (23.5%), exhibited a false-negative ARR (<50) versus that observed in the washout period. Similarly, other publications have reported insignificant effects of CCBs on the ARR (23, 24) . In contrast, nifedipine lowers the PAC values and elevates the PRA and serum potassium values in patients with PA (25, 26) . Grasko et al. (27) reported three cases of a delayed diagnosis of PA due to unremarkable ARR values caused by the administration of dihydropyridine CCB. As such, sympathetic nerve activation and medications may induce an atypical ARR, presenting with a relatively high PRA value without increasing the PAC value, as noted on day 2 in the present case.
As mentioned above, the ARR varies based on multiple factors, including day-to-day variation (13, 14) . In the present case, we observed an elevated ARR (29.0 ng/dL per ng/ mL/hr) on day 20, which was above the cut-off value for PA, under treatment with dihydropyridine CCB (nifedipine 80 mg daily) (Fig. 2) . In contrast, the ARR on day 30 was 16.9, without any changes in medications. The patient's adherence to an inpatient sodium-restricted diet (2.4 g/day, equivalent to 6.0 g of NaCl) and nifedipine may have suppressed the ARR, although the ARR also has intrinsic limitations based on the method of calculation. In most cases of PA, the PRA is less than or close to 1 ng/mL/hr (13) . Therefore, small variations in measurements affect the calculation of the ARR. Due to this effect, the ARR is mathematically highly dependent on the PRA value. There is also recognized intra-and inter-patient variation, as discussed by Tanabe et al. (13) . The guidelines of the Endocrine Society currently recommend the use of four tests to confirm the diagnosis of PA in patients with an elevated ARR: oral sodium loading, saline infusion, fludrocortisone suppression and a captopril challenge (9) . However, there is currently insufficient direct evidence to recommend one of these tests over the others. The former three tests may potentially exacerbate hypertension due to the effects of sodium loading and volume expansion. Therefore, we avoided these tests in the subacute phase of cerebral hemorrhage in the current case. The captopril challenge test is a common confirmatory assessment for PA due to its convenience and safety. However, a significant number of false-positive and false-negative results have been reported (28, 29) . The captopril test utilizes the ARR, which highly depends on the PRA value mathematically. In contrast, the rapid ACTH test proposed by Omura et al. (11) does not depend on the PRA for interpretation. Because our patient displayed a false-negative result on the captoprilchallenge test, we preferred the rapid ACTH test as a confirmatory examination. The authors subsequently introduced a maximum PAC/cortisol ratio of >0.85 after ACTHstimulation with a PRA of <1.0 ng/mL/hr and PAC of >12.0 ng/dL as criteria for probable PA in hypertensive patients. This screening test is based on the observation that aldosterone-producing adenomas produce an exaggerated amount of aldosterone in response to exogenous ACTHstimulation in the setting of sustained inhibition of renin (30) . Our patient had a PAC/cortisol ratio of >0.85, PRA value of 0.8 ng/mL/hr (<1.0) and PAC value of 23.0 ng/dL (>12.0), consistent with the criteria for PA (11) .
Recently, the disease concept of MR-associated hypertension has emerged (31) . Obesity is a known diseasemodifying risk factor for cardiovascular events in patients with MR-associated hypertension. In the present case, the patient's blood pressure control significantly improved after surgery. However, he continued to require multiple antihypertensive agents. This partial resolution of postoperative blood pressure may be attributed to the patient's obesity and lengthy disease course.
In conclusion, the PRA may be inappropriately elevated in the acute phase of cerebral hemorrhage in patients with PA, presumably due to sympathetic activation and the effects of medications. In order to make a definitive diagnosis of PA in patients with acute cerebral hemorrhage, it is necessary to reevaluate the PRA and PAC during the stable phase more than one month after presentation in most cases, although individualization is required.
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